Thurston, Springer, Miller, Herd & Titak, Inc. Novo Cure LTD Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $330 Million
- Q3 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Novo Cure LTD stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 525 shares of NVCR stock, worth $9,308. This represents 0.0% of its overall portfolio holdings.
Number of Shares
525
Previous 509
3.14%
Holding current value
$9,308
Previous $8,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NVCR
# of Institutions
262Shares Held
77MCall Options Held
1.17MPut Options Held
318K-
Black Rock Inc. New York, NY12.1MShares$215 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$210 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA7.92MShares$140 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA4.31MShares$76.4 Million0.01% of portfolio
-
Nordwand Advisors, LLC Radnor, PA3.03MShares$53.7 Million12.67% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.86B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...